234 related articles for article (PubMed ID: 35156138)
1. Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.
Iacobellis G; Basilico S; Malavazos AE
Handb Exp Pharmacol; 2022; 274():93-108. PubMed ID: 35156138
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.
Iacobellis G; Baroni MG
J Endocrinol Invest; 2022 Mar; 45(3):489-495. PubMed ID: 34643917
[TBL] [Abstract][Full Text] [Related]
3. Epicardial fat: a new cardiovascular therapeutic target.
Iacobellis G
Curr Opin Pharmacol; 2016 Apr; 27():13-8. PubMed ID: 26848943
[TBL] [Abstract][Full Text] [Related]
4. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
7. Benefits of GLP-1 Mimetics on Epicardial Adiposity.
Yaribeygi H; Maleki M; Nasimi F; Jamialahmadi T; Stanford FC; Sahebkar A
Curr Med Chem; 2023; 30(37):4256-4265. PubMed ID: 36642880
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
Yassin SA; Aroda VR
Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
[TBL] [Abstract][Full Text] [Related]
9. A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function.
Yaribeygi H; Atkin SL; Jamialahmadi T; Sahebkar A
Endocr Metab Immune Disord Drug Targets; 2020; 20(3):328-334. PubMed ID: 31612835
[TBL] [Abstract][Full Text] [Related]
10. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
11. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
12. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
Qiu M; Zhou X; Zhang M
Diabetes Obes Metab; 2022 Mar; 24(3):575-577. PubMed ID: 34729884
[No Abstract] [Full Text] [Related]
13. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Deacon CF
Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
[TBL] [Abstract][Full Text] [Related]
14. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Kashiwagi A; Shoji S; Onozawa S; Kosakai Y; Waratani M; Ito Y
J Diabetes Investig; 2022 Jul; 13(7):1175-1189. PubMed ID: 35243799
[TBL] [Abstract][Full Text] [Related]
15. New therapies for diabesity.
Bailey CJ
Curr Diab Rep; 2009 Oct; 9(5):360-7. PubMed ID: 19793506
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
17. Management of type 2 diabetes: new and future developments in treatment.
Tahrani AA; Bailey CJ; Del Prato S; Barnett AH
Lancet; 2011 Jul; 378(9786):182-97. PubMed ID: 21705062
[TBL] [Abstract][Full Text] [Related]
18. An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus.
Mahgoub MO; Ali II; Adeghate JO; Tekes K; Kalász H; Adeghate EA
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298274
[TBL] [Abstract][Full Text] [Related]
19. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
20. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
